Consano Bio to Present Clinical Development of C-1101 for Chronic Sciatica at 2026 BIO International Convention

The company recently announced initiation of a Phase 1 trial for C-1101, a potential first-in-class, non-opioid therapy for chronic sciatica BURLINGTON, Mass., June 10, 2026 /PRNewswire/ -- Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to...